Search Result

Pathways Recommended:	Membrane Transporter/Ion Channel

Results for "

T-type Ca2 channel

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Calcium Channel (29) Cytochrome P450 (2) Dopamine Receptor (5) Isotope-Labeled Compounds (1) Reference Standards (6) Sodium Channel (8)
By Research Areas:	Cancer (4) Cardiovascular Disease (8) Neurological Disease (24)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Targets Recommended: Calcium Channel CRAC Channel Na+/Ca2+ Exchanger CaSR Calmodulin CaMK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15553A

Mibefradil dihydrochloride Maximum Cited Publications 14 Publications Verification Ro 40-5967 dihydrochloride	Calcium Channel	Cardiovascular Disease Cancer
Mibefradil dihydrochloride (Ro 40-5967 dihydrochloride) is a calcium channel blocker with moderate selectivity for T-type Ca ²⁺ channels (IC₅₀s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively) .

HY-B0358

Flunarizine 5+ Cited Publications	Calcium Channel Sodium Channel Dopamine Receptor	Cardiovascular Disease Neurological Disease
Flunarizine is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine is a D₂ dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-50722

NNC 55-0396 5 Publications Verification NNC 55-0396 dihydrochloride	Calcium Channel Cytochrome P450	Cardiovascular Disease Neurological Disease Cancer
NNC 55-0396 (NNC 55-0396 dihydrochloride) is a blood-brain-barrier-permeable **T-type Ca ²⁺ channel** inhibitor and pan-P450 inhibitor. NNC 55-0396 selectively inhibits T-type Ca ²⁺ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma .

HY-B0358A

Flunarizine dihydrochloride 5+ Cited Publications	Calcium Channel Sodium Channel Dopamine Receptor	Cardiovascular Disease Neurological Disease
Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-103309

ML218 2 Publications Verification	Calcium Channel	Neurological Disease
ML218 is a potent, selective and orally active T-type Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-15553

Mibefradil Ro 40-5967	Calcium Channel	Cardiovascular Disease Cancer
Mibefradil (Ro 40-5967) is a calcium channel blocker with moderate selectivity for T-type Ca ²⁺ channels displaying IC₅₀s of 2.7 μM and 18.6 μM for T-type and L-type currents, respectively .

HY-120597

SAK3	Calcium Channel	Neurological Disease
SAK3 is a potent T-type voltage-gated **Ca ²⁺ channels (T-VGCCs*) enhancer. SAK3 enhances Cav3.1 and Cav3.3 T-type* Ca ²⁺ channel currents. Acute SAK3 administration improves memory deficits in olfactory-bulbectomized mice . SAK3 inhibits amyloid β plaque formation in APP-KI mice by activating the proteasome activity .

HY-19721

ABT-639 3 Publications Verification	Calcium Channel	Neurological Disease
ABT-639 is a novel, peripherally acting, selective T-type *Ca ²⁺* channel blocker.

HY-136909

SR33805	Calcium Channel	Cardiovascular Disease
SR33805 is a potent **Ca ²⁺ channel antagonist, with EC₅₀*s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type* but not T-type Ca ²⁺ channels. SR33805 can be used for the research of acute or chronic failing hearts .

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀ of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

HY-10388A

TTA-Q6(isomer)	Calcium Channel	Others
TTA-Q6(isomer) is an isomer of TTA-Q6. TTA-Q6 is a selective **T-type Ca ²⁺ channel** antagonist.

HY-Z8176

(Z)-Flunarizine	Sodium Channel	Neurological Disease
(Z)-Flunarizine is the (Z)-isomer of Flunarizine (HY-B0358). Flunarizine is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine is a D2 dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-B0358AR

Flunarizine dihydrochloride (Standard)	Reference Standards Calcium Channel Sodium Channel Dopamine Receptor	Neurological Disease
Flunarizine (dihydrochloride) (Standard) is the analytical standard of Flunarizine (dihydrochloride). This product is intended for research and analytical applications. Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-115681

(2R/S)-6-PNG 1 Publications Verification 6-Prenylnaringenin; (±)-6-Prenylnaringenin	Calcium Channel	Neurological Disease
(2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Ca_v3.2 T-type Ca ²⁺ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice .

HY-151452

Cav 3.2 inhibitor 3	Calcium Channel	Neurological Disease
Cav 3.2 inhibitor 3 (Compound 4) is a potent Ca_v3.2 T-type Ca ²⁺ channel inhibitor with an IC₅₀ of 0.1534 μM, and has little binding affinity to D₂ receptors .

HY-B0358AS

Flunarizine-d8 dihydrochloride	Sodium Channel Dopamine Receptor Calcium Channel Isotope-Labeled Compounds	Neurological Disease
Flunarizine-d₈ dihydrochloride is deuterated labeled Flunarizine dihydrochloride (HY-B0358A). Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-103309S

ML218-d9	Calcium Channel	Neurological Disease
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-115681R

(2R/S)-6-PNG (Standard) 6-Prenylnaringenin (Standard); (±)-6-Prenylnaringenin (Standard)	Reference Standards Calcium Channel	Neurological Disease
(2R/S)-6-PNG (Standard) is the analytical standard of (2R/S)-6-PNG. This product is intended for research and analytical applications. (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice .

HY-101616

ABT-639 hydrochloride	Calcium Channel	Neurological Disease
ABT-639 hydrochloride is a novel, peripherally acting, selective T-type *Ca ²⁺* channel blocker.

HY-P5869

Kurtoxin	Calcium Channel Sodium Channel	Neurological Disease
Kurtoxin is a selective Cav3 (T-type) voltage-gated **Ca ²⁺ channel gating inhibitor with a K_d** of 15 nM for Cav3.1 (α1G T-type) Ca ²⁺ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca ²⁺ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na ⁺ channel .

HY-10388

TTA-Q6 1 Publications Verification	Calcium Channel	Neurological Disease
TTA-Q6 is a selective **T-type Ca ²⁺ channel** antagonist, which can be used in the research of neurological disease .

HY-103313

SR33805 oxalate	Calcium Channel	Cardiovascular Disease
SR33805 oxalate is a potent **Ca ²⁺ channel antagonist, with EC₅₀*s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 oxalate blocks L-type* but not T-type Ca ²⁺ channels. SR33805 oxalate can be used for the research of acute or chronic failing hearts .

HY-B0358R

Flunarizine (Standard)	Reference Standards Calcium Channel Sodium Channel Dopamine Receptor	Neurological Disease
Flunarizine (Standard) is the analytical standard of Flunarizine. This product is intended for research and analytical applications. Flunarizine is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine is a D₂ dopamine receptor antagonist. Flunarizine shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-151451

Cav 3.2 inhibitor 2	Calcium Channel	Neurological Disease
Cav 3.2 inhibitor 2 is a Ca_v3.2 T-type Ca ²⁺ channels inhibitor with an IC₅₀ of 0.09339 μM under -80mV holding potential. Cav 3.2 inhibitor 2 potently suppresses T-channel-dependent somatic and visceral pain in mice. Cav 3.2 inhibitor 2 can be used for the research of intractable pain .

HY-10388R

TTA-Q6 (Standard)	Reference Standards Calcium Channel	Neurological Disease
TTA-Q6 (Standard) is the analytical standard of TTA-Q6 (HY-10388). This product is intended for research and analytical applications. TTA-Q6 is a selective T-type Ca2+ channel antagonist, which can be used in the research of neurological disease .

HY-103309A

ML218 hydrochloride	Calcium Channel	Neurological Disease
ML218 hydrochloride is a potent, selective and orally active T-type Ca ²⁺ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 hydrochloride inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 hydrochloride has no significant inhibition of L- or N-type calcium channels, K_ATP or hERG potassium channels. ML218 hydrochloride can penetrate the blood-brain barrier .

HY-10388AR

TTA-Q6(isomer) (Standard)	Reference Standards Calcium Channel	Others
TTA-Q6(isomer) (Standard) is the analytical standard of TTA-Q6(isomer) (HY-10388A). This product is intended for research and analytical applications. TTA-Q6(isomer) is an isomer of TTA-Q6. TTA-Q6 is a selective T-type Ca2+ channel antagonist.

HY-50722B

NNC 55-0396 free base	Calcium Channel Cytochrome P450	Cardiovascular Disease Neurological Disease Cancer
NNC 55-0396 free base is a blood-brain-barrier-permeable **T-type Ca ²⁺ channel** inhibitor and pan-P450 inhibitor. NNC 55-0396 free base selectively inhibits T-type Ca²⁺ channels, suppresses HIF-1α expression and stability and inhibits Kv currents. NNC 55-0396 free base reduces brain infarct and attenuates neurological dysfunction. NNC 55-0396 free base inhibits the activity of multiple P450 enzymes. NNC 55-0396 (free base) can be used for the research of brain injury, hypertension, and glioblastoma .

HY-103309R

ML218 (Standard)	Reference Standards Calcium Channel	Neurological Disease
ML218 (Standard) is the analytical standard of ML218 (HY-103309). This product is intended for research and analytical applications. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

HY-105415

U 92032	Calcium Channel Sodium Channel	Neurological Disease
U 92032 is a T-type **Ca ²⁺ channel** antagonist. U 92032 inhibits Na ⁺ channels. U-92032 inhibits thalamic oscillations. U 92032 can be used in the research of neurological diseases .

Cat. No.	Product Name	Target	Research Area

HY-P1079

ω-Agatoxin TK	Calcium Channel	Neurological Disease
ω-Agatoxin TK, a peptidyl toxin of the venom of Agelenopsis aperta, is a potent and selective P/Q type Ca ²⁺ channel blocker. ω-Agatoxin TK inhibits the high K ⁺ depolarisation-induced rise in internal Ca ²⁺ in cerebral isolated nerve endings with an IC₅₀ of of 60 nM. ω-Agatoxin TK has no effect on L-type, N-type, or T-type calcium channels .

HY-P5869

Kurtoxin	Calcium Channel Sodium Channel	Neurological Disease
Kurtoxin is a selective Cav3 (T-type) voltage-gated **Ca ²⁺ channel gating inhibitor with a K_d** of 15 nM for Cav3.1 (α1G T-type) Ca ²⁺ channel. Kurtoxin can interact with high affinity with native neuronal high-threshold L-type, N-type, and P-type Ca ²⁺ channels in central and peripheral neurons. Kurtoxin also shows cross-reactivity with voltage-gated Na ⁺ channel .

Cat. No.	Product Name	Chemical Structure

HY-B0358AS

Flunarizine-d8 dihydrochloride
Flunarizine-d₈ dihydrochloride is deuterated labeled Flunarizine dihydrochloride (HY-B0358A). Flunarizine dihydrochloride is a potent dual Na ⁺/Ca ²⁺ channel (T-type) blocker. Flunarizine dihydrochloride is a D₂ dopamine receptor antagonist. Flunarizine dihydrochloride shows anticonvulsive and antimigraine activity, and peripheral vasodilator effects .

HY-103309S

ML218-d9
ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

ML218-d9

ML218-d₉ is the deuterium labeled ML218. ML218 is a potent, selective and orally active T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) inhibitor with IC₅₀s of 310 nM and 270 nM for Cav3.2 and Cav3.3, respectively. ML218 inhibits the burst activity in subthalamic nucleus (STN) neurons. ML218 has no significant inhibition of L- or N-type calcium channels, KATP or hERG potassium channels. ML218 can penetrate the blood-brain barrier .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: